$ZIVO
Zivo Bioscience, Inc.

2023 Q4 Form 10-Q Financial Statement

#000165495423014165 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $11.80K $11.80K $0.00
YoY Change
Cost Of Revenue $7.670K $7.670K $0.00
YoY Change
Gross Profit $4.130K $4.130K $0.00
YoY Change
Gross Profit Margin 35.0% 35.0%
Selling, General & Admin $1.588M $1.360M $1.397M
YoY Change -25.03% -2.65% 10.57%
% of Gross Profit 38456.42% 32929.78%
Research & Development $312.5K $220.7K $603.1K
YoY Change -39.83% -63.41% -23.89%
% of Gross Profit 7565.86% 5342.69%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.901M $1.577M $2.000M
YoY Change -27.94% -21.18% -2.72%
Operating Profit -$1.897M -$1.572M -$2.000M
YoY Change -21.38% -2.72%
Interest Expense -$7.080K $32.74K $4.245K
YoY Change 133.66% 671.17% 1921.43%
% of Operating Profit
Other Income/Expense, Net -$4.880K $252.5K -$4.245K
YoY Change -6048.98% -103.49%
Pretax Income -$1.909M -$1.820M -$2.004M
YoY Change -27.73% -9.2% 26.51%
Income Tax
% Of Pretax Income
Net Earnings -$1.909M -$1.825M -$2.004M
YoY Change -27.73% -8.95% 3.61%
Net Earnings / Revenue -16174.15% -15465.44%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.99 -$1.05 -$212.8K
COMMON SHARES
Basic Shares Outstanding 1.820M shares 10.45M shares 9.420M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $274.4K $1.480M $3.386M
YoY Change -84.75% -56.29% -68.66%
Cash & Equivalents $274.4K $1.485M $3.386M
Short-Term Investments
Other Short-Term Assets $147.3K $460.0K $342.6K
YoY Change 43.78% 34.28% 159.35%
Inventory
Prepaid Expenses
Receivables $3.740K $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $425.4K $1.948M $3.729M
YoY Change -77.63% -47.76% -65.9%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $130.3K $154.2K $242.8K
YoY Change -41.11% -36.51% 572.49%
TOTAL ASSETS
Total Short-Term Assets $425.4K $1.948M $3.729M
Total Long-Term Assets $130.3K $154.2K $242.8K
Total Assets $555.7K $2.102M $3.971M
YoY Change -73.82% -47.07% -63.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $993.1K $643.8K $607.0K
YoY Change 102.39% 6.07% -16.72%
Accrued Expenses $1.149M $823.8K $364.8K
YoY Change 188.51% 125.81% -15.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $1.130M $139.7K
YoY Change 708.93%
Long-Term Debt Due $240.0K $240.0K $240.0K
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $2.762M $3.174M $2.315M
YoY Change 36.19% 37.1% -34.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $20.00K $131.9K
YoY Change -100.0% -84.84% 3779.71%
Total Long-Term Liabilities $0.00 $22.03K $131.9K
YoY Change -100.0% -83.3% 3779.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.762M $3.174M $2.315M
Total Long-Term Liabilities $0.00 $22.03K $131.9K
Total Liabilities $2.762M $3.196M $2.447M
YoY Change 29.43% 30.61% -31.09%
SHAREHOLDERS EQUITY
Retained Earnings -$123.6M -$121.7M -$113.2M
YoY Change 6.72% 7.52% 7.71%
Common Stock $2.383K $1.742K $9.420K
YoY Change -99.21% -81.51% 0.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.206M -$1.094M $1.524M
YoY Change
Total Liabilities & Shareholders Equity $555.7K $2.102M $3.971M
YoY Change -73.82% -47.07% -63.8%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$1.909M -$1.825M -$2.004M
YoY Change -27.73% -8.95% 3.61%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$719.9K -$1.970M -$1.488M
YoY Change -50.25% 32.37% -17.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -495.0K 3.430M -209.5K
YoY Change 254.35% -1737.0% -112.31%
NET CHANGE
Cash From Operating Activities -719.9K -1.970M -1.488M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities -495.0K 3.430M -209.5K
Net Change In Cash -1.215M 1.460M -1.698M
YoY Change -23.43% -186.0% 1600.12%
FREE CASH FLOW
Cash From Operating Activities -$719.9K -$1.970M -$1.488M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001101026
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1741610 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1569943 shares
CY2023Q3 zivo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Ca
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossCA
0 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40449
dei Entity Registrant Name
EntityRegistrantName
Zivo Bioscience, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0699977
dei Entity Address Address Line1
EntityAddressAddressLine1
21 E. Long Lake Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Bloomfield Hills
dei Entity Address State Or Province
EntityAddressStateOrProvince
MI
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
48304
dei City Area Code
CityAreaCode
248
dei Local Phone Number
LocalPhoneNumber
452 9866
dei Security12b Title
Security12bTitle
Common Stock, par value$0.001 per share
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105919 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
22027 usd
dei Trading Symbol
TradingSymbol
ZIVO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1819523 shares
CY2023Q3 zivo Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalent
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalent
1484644 usd
CY2022Q4 zivo Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalent
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalent
1799263 usd
CY2023Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
2593 usd
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
460632 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
102416 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1947869 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1901679 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
122110 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189282 usd
CY2023Q3 us-gaap Security Deposit
SecurityDeposit
32058 usd
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
32058 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
154168 usd
CY2022Q4 us-gaap Other Assets
OtherAssets
221340 usd
CY2023Q3 us-gaap Assets
Assets
2102037 usd
CY2022Q4 us-gaap Assets
Assets
2123019 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
643812 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
490670 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110398 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99259 usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
240000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
240000 usd
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
57906 usd
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
525904 usd
CY2023Q3 zivo Deferred Rd Obligations Participation Agreements Related Parties
DeferredRDObligationsParticipationAgreementsRelatedParties
19316 usd
CY2022Q4 zivo Deferred Rd Obligations Participation Agreements Related Parties
DeferredRDObligationsParticipationAgreementsRelatedParties
175427 usd
CY2023Q3 us-gaap Loans Payable
LoansPayable
1129696 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
0 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
149145 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
98286 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
823779 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
398176 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3174052 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2027722 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22027 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
105919 usd
CY2023Q3 us-gaap Liabilities
Liabilities
3196079 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2133641 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1741610 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1569943 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
1742 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1570 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
120577382 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
115792337 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121673166 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115804529 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1094042 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10622 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2102037 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2123019 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11800 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15850 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2023Q3 us-gaap Revenues
Revenues
11800 usd
CY2022Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
15850 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Other Restructuring Costs
OtherRestructuringCosts
7670 usd
CY2022Q3 us-gaap Other Restructuring Costs
OtherRestructuringCosts
0 usd
us-gaap Other Restructuring Costs
OtherRestructuringCosts
8371 usd
us-gaap Other Restructuring Costs
OtherRestructuringCosts
0 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7670 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8371 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
4130 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
7479 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1355865 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1396989 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4309343 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4373285 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
220653 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
603105 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1064563 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1720925 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1576518 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
2000094 usd
us-gaap Operating Expenses
OperatingExpenses
5373906 usd
us-gaap Operating Expenses
OperatingExpenses
6094210 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1572388 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2000094 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5366427 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6094210 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
32736 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
4245 usd
us-gaap Interest Expense
InterestExpense
67498 usd
us-gaap Interest Expense
InterestExpense
10288 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
219798 usd
CY2022Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
434712 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2023Q3 us-gaap Other Expenses
OtherExpenses
252534 usd
CY2022Q3 us-gaap Other Expenses
OtherExpenses
4245 usd
us-gaap Other Expenses
OtherExpenses
502210 usd
us-gaap Other Expenses
OtherExpenses
10288 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1824922 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2004339 usd
us-gaap Net Income Loss
NetIncomeLoss
-5868637 usd
us-gaap Net Income Loss
NetIncomeLoss
-6104498 usd
CY2023Q3 zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-1.05
CY2022Q3 zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-1.28
zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-3.64
zivo Basic And Diluted Net Income Loss Per Share
BasicAndDilutedNetIncomeLossPerShare
-3.89
CY2023Q3 zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
1735887 shares
CY2022Q3 zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
1569943 shares
zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
1610861 shares
zivo Weighted Average Stock Basic And Diluted Shares Outstanding
WeightedAverageStockBasicAndDilutedSharesOutstanding
1569943 shares
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
3010423 usd
CY2022Q3 zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
518161 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-2004339 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1524245 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-3144832 usd
CY2023Q3 zivo Private Offering Issuance Of Stock And Warrants Amount
PrivateOfferingIssuanceOfStockAndWarrantsAmount
3634963 usd
CY2023Q3 zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
240749 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1824922 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1094042 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6042209 usd
zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
1586534 usd
us-gaap Net Income Loss
NetIncomeLoss
-6104498 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1524245 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10622 usd
zivo Private Offering Issuance Of Stock And Warrants Amount
PrivateOfferingIssuanceOfStockAndWarrantsAmount
3634963 usd
zivo Employee And Director Equity Based Compensation
EmployeeAndDirectorEquityBasedCompensation
710661 usd
zivo Warrants Issued With Related Party Note
WarrantsIssuedWithRelatedPartyNote
439593 usd
us-gaap Net Income Loss
NetIncomeLoss
-5868637 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1094042 usd
us-gaap Profit Loss
ProfitLoss
-5868637 usd
us-gaap Profit Loss
ProfitLoss
-6104498 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
67172 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
58159 usd
zivo Amortization Of Deferred Rd Obligations Participation Agreements
AmortizationOfDeferredRDObligationsParticipationAgreements
-624110 usd
zivo Amortization Of Deferred Rd Obligations Participation Agreements
AmortizationOfDeferredRDObligationsParticipationAgreements
-702045 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
434712 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
zivo Employee And Director Equity Compensations Operating Activety
EmployeeAndDirectorEquityCompensationsOperatingActivety
710661 usd
zivo Employee And Director Equity Compensations Operating Activety
EmployeeAndDirectorEquityCompensationsOperatingActivety
1586534 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-358217 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-284487 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-99536 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-47352 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-72752 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-32238 usd
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
0 usd
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-29058 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2593 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
729140 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-100605 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5084160 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5655590 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
605600 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
628600 usd
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
471023 usd
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
488911 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
1000000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
3634963 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4769540 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
139689 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-314620 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5515901 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1799264 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8901875 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1484644 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3385974 usd
us-gaap Interest Paid Net
InterestPaidNet
16639 usd
us-gaap Interest Paid Net
InterestPaidNet
8493 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022Q3 zivo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Ca
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossCA
36731 shares
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
240750 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
518161 usd
zivo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Ca
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossCA
10878 shares
zivo Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Ca
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossCA
65481 shares
us-gaap Share Based Compensation
ShareBasedCompensation
710661 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1586534 usd
CY2020Q4 zivo Lease Agreement Term
LeaseAgreementTerm
25 ½ month
CY2020Q4 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
54993 usd
CY2020Q4 zivo Operating Lease Commencement Date
OperatingLeaseCommencementDate
2021-02-01
CY2020Q4 zivo Rent Description
RentDescription
Rent is $3,291 per month from January 15, 2021 to January 31, 2022 and $1,154 from February 1, 2022 to January 31, 2023. On June 5, 2022, the Company exercised an option to extend the lease through December 31, 2024. The lease extension rent is $2,261 per month for calendar year 2023, and $2,300 per month for calendar year 2024, and totals an additional rent obligation of $54,743 of rent over the extension period
CY2022Q1 zivo Lease Agreement Term
LeaseAgreementTerm
34-month
CY2022Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
232464 usd
CY2022Q1 zivo Operating Lease Commencement Date
OperatingLeaseCommencementDate
2022-04-29
CY2022Q1 zivo Rent Description
RentDescription
Rent is $7,265 per month from commencement to November 30, 2022, $7,466 from November 30, 2022 to November 30, 2023, and $7,668 from November 30, 2023 to the lease end date
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
122110 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
189282 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110398 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
99259 usd
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
22027 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
105918 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
132425 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
205177 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
27236 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
27479 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
81707 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
74770 usd
zivo Operating Lease Weighted Average Remaining Lease Term
OperatingLeaseWeightedAverageRemainingLeaseTerm
P1Y2M15D
CY2022 zivo Operating Lease Weighted Average Remaining Lease Term
OperatingLeaseWeightedAverageRemainingLeaseTerm
P1Y11M8D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1100 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1100 pure
zivo Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
86720 usd
zivo Cash Paid For Amounts Included In The Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
48849 usd
zivo Non Cash Investment In Rou Asset
NonCashInvestmentInRouAsset
0 usd
zivo Non Cash Investment In Rou Asset
NonCashInvestmentInRouAsset
195804 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
29489 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
112407 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
141896 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9471 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
132425 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
110398 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22027 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
18.66
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y
CY2023Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate
ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
0.0373 pure
CY2023Q2 zivo Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Volatility
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsVolatility
0.9989 pure
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000000 usd
zivo Less Unamortized Debt Discount
LessUnamortizedDebtDiscount
-4882 usd
zivo Carrying Value Of Term Loan
CarryingValueOfTermLoan
995118 usd

Files In Submission

Name View Source Status
zivo-20230930_cal.xml Edgar Link unprocessable
0001654954-23-014165-index-headers.html Edgar Link pending
0001654954-23-014165-index.html Edgar Link pending
0001654954-23-014165.txt Edgar Link pending
0001654954-23-014165-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zivo-20230930.xsd Edgar Link pending
zivo_10q.htm Edgar Link pending
zivo_ex311.htm Edgar Link pending
zivo_ex312.htm Edgar Link pending
zivo_ex321.htm Edgar Link pending
zivo_ex322.htm Edgar Link pending
zivo-20230930_pre.xml Edgar Link unprocessable
zivo_10q_htm.xml Edgar Link completed
zivo-20230930_lab.xml Edgar Link unprocessable
zivo-20230930_def.xml Edgar Link unprocessable